Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Executive summary

Budget impact of Ficerafusp alfa

3 evidence topics · 15 sources

Summary

Ficerafusp alfa is investigational. No price, wholesale acquisition cost, budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then” and expects an interim analysis of FORTIFI-HN01 in mid-2027 “to support a potential approval and U.S. launch in 2028.” In FORTIFI-HN01, every participant receives pembrolizumab 200 mg every 3 weeks for up to 35 cycles, with ficerafusp alfa or placebo given weekly until disease progression or unacceptable toxicity; the cost of ficerafusp alfa would therefore be added to the cost of pembrolizumab for each treated patient.

Summary: eligible population inputs

The American Cancer Society estimates 60,480 new cases of oral cavity and pharynx cancer and 12,290 new cases of laryngeal cancer in the United States in 2026; these counts include all histologies and both HPV-negative and HPV-positive disease. Bicara's Form 10-K states that over 90% of head and neck cancer cases are of squamous cell origin, that an estimated 10% of patients have metastatic disease at diagnosis and “up to 30% of additional patients develop a recurrence or metastases over time after initial treatment for advanced HNSCC”, and that an estimated 80% of recurrent or metastatic HNSCC is HPV-negative. In a U.S. real-world cohort treated in the first-line recurrent or metastatic setting, 60.4% of participants had non-HPV associated disease, and 1410 participants (54.7%) received anti-PD-1 monotherapy, 577 (22.4%) anti-PD-1 plus chemotherapy, and 590 (22.9%) cetuximab plus chemotherapy. The pivotal trial requires PD-L1 CPS ≥1; in the first-line trial described in the pembrolizumab label, 85% of tumors had CPS ≥1. Bicara's presentation estimates “~18K” HPV-negative patients newly diagnosed each year in the United States (“~50K” in the United States, EU5, and Japan), based on “Tessellon patient flow modeling; SEER; country-specific registries; literature review”.

Summary: comparator regimen costs and cost of recurrent or metastatic disease

Merck lists the price of pembrolizumab at $12,517.44 for each dose given every 3 weeks and $25,034.88 for each dose given every 6 weeks, current as of September 2026. The pembrolizumab label gives treatment for HNSCC as “Until disease progression, unacceptable toxicity, or up to 24 months”, and median real-world time on first-line pembrolizumab monotherapy was 4.2 months (95% CI, 3.5–4.6). Lilly lists cetuximab at $17,235.60 per month for an average-sized patient. In a retrospective study using the Vector Oncology Data Warehouse, the mean monthly health care cost was $14,391 (95% CI, 12,739-16,044), with hospitalization representing about 57% of the total. Among 716 participants treated before or after the introduction of immuno-oncology agents, per patient per month total costs of care in first-line post-platinum therapy were $11,535 after and $9,054 before (p=.002). In 2004 to 2008 Medicare and commercial claims, 6-month incremental adjusted total costs were $60,414 per patient for metastatic and $21,141 per patient for recurrent head and neck cancer. In SEER-Medicare, recurrence of locally advanced HNSCC was associated with higher monthly health care costs of $3,831 (resected) and $4,730 (unresected). None of these cost studies is restricted to HPV-negative disease.